Since HAS shares similar clinical and pathological features with AFP-producing gastric cancer, and prior reports have suggested the favorable efficacy of PD-1 blockade in HAS, this study aimed to evaluate the response of HAS to immunotherapy.19 The gene discussed is AFP; the disease is gastric cancer.